Literature DB >> 32946228

Identification, Structure-Activity Relationship, and Biological Characterization of 2,3,4,5-Tetrahydro-1H-pyrido[4,3-b]indoles as a Novel Class of CFTR Potentiators.

Nicoletta Brindani1, Ambra Gianotti2, Simone Giovani1, Francesca Giacomina1, Paolo Di Fruscia1, Federico Sorana1, Sine Mandrup Bertozzi3, Giuliana Ottonello3, Luca Goldoni3, Ilaria Penna1, Debora Russo1, Maria Summa3, Rosalia Bertorelli3, Loretta Ferrera2, Emanuela Pesce2, Elvira Sondo2, Luis J V Galietta4,5, Tiziano Bandiera1, Nicoletta Pedemonte2, Fabio Bertozzi1.   

Abstract

Cystic fibrosis (CF) is a life-threatening autosomal recessive disease, caused by mutations in the CF transmembrane conductance regulator (CFTR) chloride channel. CFTR modulators have been reported to address the basic defects associated with CF-causing mutations, partially restoring the CFTR function in terms of protein processing and/or channel gating. Small-molecule compounds, called potentiators, are known to ameliorate the gating defect. In this study, we describe the identification of the 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole core as a novel chemotype of potentiators. In-depth structure-activity relationship studies led to the discovery of enantiomerically pure 39 endowed with a good efficacy in rescuing the gating defect of F508del- and G551D-CFTR and a promising in vitro druglike profile. The in vivo characterization of γ-carboline 39 showed considerable exposure levels and good oral bioavailability, with detectable distribution to the lungs after oral administration to rats. Overall, these findings may represent an encouraging starting point to further expand this chemical class, adding a new chemotype to the existing classes of CFTR potentiators.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32946228      PMCID: PMC8011931          DOI: 10.1021/acs.jmedchem.0c01050

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  49 in total

1.  Development of a virtual screening method for identification of "frequent hitters" in compound libraries.

Authors:  Olivier Roche; Petra Schneider; Jochen Zuegge; Wolfgang Guba; Manfred Kansy; Alexander Alanine; Konrad Bleicher; Franck Danel; Eva-Maria Gutknecht; Mark Rogers-Evans; Werner Neidhart; Henri Stalder; Michael Dillon; Eric Sjögren; Nader Fotouhi; Paul Gillespie; Robert Goodnow; William Harris; Phil Jones; Mikio Taniguchi; Shinji Tsujii; Wolfgang von der Saal; Gerd Zimmermann; Gisbert Schneider
Journal:  J Med Chem       Date:  2002-01-03       Impact factor: 7.446

2.  Physiology of epithelial chloride and fluid secretion.

Authors:  Raymond A Frizzell; John W Hanrahan
Journal:  Cold Spring Harb Perspect Med       Date:  2012-06       Impact factor: 6.915

3.  Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive.

Authors:  G M Denning; M P Anderson; J F Amara; J Marshall; A E Smith; M J Welsh
Journal:  Nature       Date:  1992-08-27       Impact factor: 49.962

4.  Binding of tetrahydrocarboline derivatives at human 5-HT5A receptors.

Authors:  Nantaka Khorana; Carol Smith; Kathy Herrick-Davis; Anil Purohit; Milt Teitler; Brian Grella; Małgorzata Dukat; Richard A Glennon
Journal:  J Med Chem       Date:  2003-08-28       Impact factor: 7.446

5.  Beta and gamma carboline derivatives as potential anti-Alzheimer agents: A comparison.

Authors:  Robert Otto; Robert Penzis; Friedemann Gaube; Thomas Winckler; Dorothea Appenroth; Christian Fleck; Christian Tränkle; Jochen Lehmann; Christoph Enzensperger
Journal:  Eur J Med Chem       Date:  2014-09-16       Impact factor: 6.514

6.  CFTR activation in human bronchial epithelial cells by novel benzoflavone and benzimidazolone compounds.

Authors:  Emanuela Caci; Chiara Folli; Olga Zegarra-Moran; Tonghui Ma; Mark F Springsteel; Robert E Sammelson; Michael H Nantz; Mark J Kurth; A S Verkman; Luis J V Galietta
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2003-03-21       Impact factor: 5.464

7.  Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.

Authors:  Mica Skilton; Ashma Krishan; Sanjay Patel; Ian P Sinha; Kevin W Southern
Journal:  Cochrane Database Syst Rev       Date:  2019-01-07

Review 8.  Peripheral Protein Quality Control as a Novel Drug Target for CFTR Stabilizer.

Authors:  Ryosuke Fukuda; Tsukasa Okiyoneda
Journal:  Front Pharmacol       Date:  2018-09-27       Impact factor: 5.810

Review 9.  Emerging Therapeutic Approaches for Cystic Fibrosis. From Gene Editing to Personalized Medicine.

Authors:  Iwona Pranke; Anita Golec; Alexandre Hinzpeter; Aleksander Edelman; Isabelle Sermet-Gaudelus
Journal:  Front Pharmacol       Date:  2019-02-27       Impact factor: 5.810

10.  PAINS in the assay: chemical mechanisms of assay interference and promiscuous enzymatic inhibition observed during a sulfhydryl-scavenging HTS.

Authors:  Jayme L Dahlin; J Willem M Nissink; Jessica M Strasser; Subhashree Francis; LeeAnn Higgins; Hui Zhou; Zhiguo Zhang; Michael A Walters
Journal:  J Med Chem       Date:  2015-02-21       Impact factor: 8.039

View more
  2 in total

1.  Antischistosomal tetrahydro-γ-carboline sulfonamides.

Authors:  Rongguo Ren; Xiaofang Wang; Derek A Leas; Cécile Häberli; Monica Cal; Yuxiang Dong; Marcel Kaiser; Jennifer Keiser; Jonathan L Vennerstrom
Journal:  Bioorg Med Chem Lett       Date:  2022-01-12       Impact factor: 2.823

Review 2.  Pharmacological Modulation of Ion Channels for the Treatment of Cystic Fibrosis.

Authors:  Madalena C Pinto; Iris A L Silva; Miquéias Lopes-Pacheco; Miriam F Figueira; Margarida D Amaral
Journal:  J Exp Pharmacol       Date:  2021-07-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.